Evidence map›Paper›PMID 42326771›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Longitudinal brain structural changes during clozapine treatment: associations with neuroreceptor architecture and clinical response.

Bridget King, Dara M Cannon, Nicolas A Crossley, Alfonso Gonzalez-Valderrama, Brian Hallahan, Wi Hoon Jung, Matthew J Kempton, Seoyoung Kim, Andrew J Lawrence, James H MacCabe and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bridget KingDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0001-5197-456
Dara M CannonClinical Neuroimaging Laboratory, Centre for Neuroimaging, Cognition and Genomics (NICOG), Galway.
Nicolas A CrossleyDepartment of Psychiatry, Pontificia, Universidad Catolica de Chile, Santiago, Chile.
Alfonso Gonzalez-ValderramaSchool of Medicine, Finis Terrae University, Santiago, Chile.
Brian HallahanClinical Neuroimaging Laboratory, Centre for Neuroimaging, Cognition and Genomics (NICOG), Galway.
Wi Hoon JungDepartment of Psychology, Gachon University, Gyeonggi-do, Republic of Korea.
Matthew J KemptonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Seoyoung KimDepartment of Psychiatry, Seoul National University Bundang Hospital, Gyeonggi-do, Seoul, Republic of Korea.
Andrew J LawrenceDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
James H MacCabeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-6754-1018
Colm McDonaldClinical Neuroimaging Laboratory, Centre for Neuroimaging, Cognition and Genomics (NICOG), Galway.
Cristián MenaCentro de Interés Nacional para Investigación e Innovación en Niñez, Adolescencia, Resiliencia y Adversidad (IINARA), Santiago, Chile.
Shinichiro NakajimaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo.
Andrew PapaleUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Samira RaminfardUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Deepak K SarpalUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Hyejin SimDepartment of Brain & Cognitive Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.
Giulia TronchinClinical Neuroimaging Laboratory, Centre for Neuroimaging, Cognition and Genomics (NICOG), Galway.
Lauri TuominenUniversity of Ottawa Institute of Mental Health Research, Ottawa, ON, Canada.
Euitae KimDepartment of Psychiatry, Seoul National University Bundang Hospital, Gyeonggi-do, Seoul, Republic of Korea.
Alice EgertonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Funding

Neural Biomarkers of Clozapine ResponseK23MH110661 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SARPAL, DEEPAK K · 2016 to 2019
$725k
NIMH NIH HHS K23 MH110661Wellcome Trust
6 · The paper itself

Abstract

In treatment-resistant schizophrenia, clozapine treatment has been associated with longitudinal reductions in subcortical volumes, ventricular enlargement, and widespread cortical thinning. However, it is unknown how these structural changes relate to clozapine's pharmacological profile and clinical efficacy. We combined five longitudinal datasets with MRI acquired before and on average 5 months after clozapine initiation in 143 individuals to quantify brain structural changes and their association with normative maps relating to neuroreceptor architecture and physiological systems, and improvement in symptom severity. Clozapine treatment was associated with grey matter volume reductions across multiple subcortical regions (including the amygdala, hippocampus, thalamus, caudate, putamen and nucleus accumbens), increases in pallidal volume, ventricular enlargement, and widespread cortical thinning. Cortical regions showing the greatest magnitude of thinning corresponded to areas with higher normative densities of serotonergic 5-HT

Identifiers

PMID42326771
PMCPMC13278268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.